Partners Onyx And Bayer Settle Next-Gen Nexavar Lawsuit, Enter New Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Onyx dropped its lawsuit against partner Bayer in exchange for an agreement that lets it share the financial rewards of the compound at the heart of the controvers, regorafenib, now in Phase III for oncology indications.
You may also be interested in...
Building On Bayer
Onyx has learned a lot in its almost twenty year history with Bayer, managing through the upside and downside of having a Big Pharma partner.
Nexavar Expansion Plans Suffer Another Blow With Failed Lung Cancer Trial
Failed MISSION trial closes a door for Bayer/Onyx’s Nexavar in non-small cell lung cancer. Meanwhile, follow-on regorafenib, also partnered by Bayer and Onyx, is poised for submission in the U.S. and Europe for metastatic colon cancer.
Nexavar Expansion Plans Suffer Another Blow With Failed Phase III Lung Cancer Trial
Failed MISSION trial closes a door for Bayer/Onyx’s Nexavar in non-small cell lung cancer. Meanwhile, follow-on regorafenib, also partnered by Bayer and Onyx, is poised for submission in the U.S. and Europe for metastatic colon cancer, with ASCO presentations ahead.